<table name="logo_release" border="0" cellspacing="10" cellpadding="5" align="right">   <tbody>    <tr>     <td><img src="https://mma.prnasia.com/media2/1780796/LifeSpan_Vision_Ventures_Logo.jpg?p=medium600" border="0" alt="" title="logo" hspace="0" vspace="0" width="118" /></td>    </tr>   </tbody>  </table>  <p><span class="legendSpanClass">NORWALK, Conn.</span>, <span class="legendSpanClass">Feb. 19, 2026</span> /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed financing alongside Freeflow Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, and other early investors.</p>  <p>Sift Biosciences is developing a peptide-based immunotherapy platform designed to harness pre-existing immune memory. The company's approach aims to generate more consistent immune engagement by activating memory T cells that already exist in patients, with potential applications across oncology and autoimmune disease. Sift is initially advancing programs in immunologically &quot;cold&quot; solid tumors, including microsatellite-stable colorectal and ovarian cancers, while also exploring immune disease programs where more selective control of immune responses could be therapeutic.</p>  <p>&quot;This financing will support in vivo efficacy studies, expansion of our AI powered peptide discovery engine, and lead candidate selection,&quot; said&nbsp;Clare Lou, Ph.D., CEO and Cofounder of Sift Biosciences. &quot;We are excited to partner with Lifespan Vision Ventures and this strong investor syndicate as we advance our initial pipeline toward the clinic.&quot;</p>  <p>&quot;We are pleased to support Sift because they are applying a clear immunology insight with a platform built to scale,&quot; said Altar Munis, Ph.D., Associate at Lifespan Vision Ventures. &quot;The platform is designed to engage antigen-experienced memory T cells and tune response magnitude and phenotype, with potential applications beyond oncology in autoimmunity and broader immune dysfunction that increases with age.&quot;</p>  <p>As part of the financing, Altar Munis, Ph.D., Associate at Lifespan Vision Ventures, and Kevin Barrett, Managing Partner at Freeflow Ventures will join Sift Biosciences' Board of Directors.</p>  <p><b> About Lifespan Vision Ventures </b></p>  <p>Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan.</p>  <p><b>Contact:&nbsp;</b><a href="mailto:info@lifespanvision.com" target="_blank" rel="nofollow" style="color: #0000FF">info@lifespanvision.com</a></p>  <p>&nbsp;</p>